Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. The Dow is a highly recognized and influential stock market index that ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

(This Feb. 10 story has been refiled to say 'LOEs (loss of exclusivity),' not 'LOEs (levels of evidence),' in paragraph 13) ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...